• For Acyclovir Lauriad®, the Company has engaged discussion with European regulatory agencies and obtained a registration slot. While standard drug development usually requests a second phase III trial prior to file for market authorization, BioAlliance Pharma has initiated promising discussion with European and US agencies to recognize Acyclovir Lauriad® clinical benefits and allow a much shorter process.
  • S1 2010 record turnover with €21.3 M versus €4.1 M for the same period in 2009. BioAlliance has again shown the capacity to reach on time important milestones, including its new European partnership with Therabel (March 2010), followed by the FDA approval of Loramyc®/ Oravig® (April 2010).


More details
 

Find an actor

MedTech Investing Europe 2018 (MTi)24.04.2018

The 26th MedTech Investing Europe Conference will be held on 24 and 25 April 2018 at the Royal Savoy Hotel in...

Anergis and Mymetics Start Research Collaboration Project

Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines,...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn